CA-SUGARCRM
14.1.2020 17:02:09 CET | Business Wire | Press release
SugarCRM Inc.® , the company that enables organizations to create customers for life, today announced its Winter ‘20 release, showcasing a new renewals console, along with additional features designed to improve the lead funnel, increase renewal rates for recurring revenue models, and optimize first-response resolution rates inside customer support centers.
The Renewals Console, a feature within Sugar Sell , is a significant differentiator for Sugar. Where other CRMs require extensive customization or third-party integration for duration-based renewable services, Sugar is providing this feature as core functionality.
“The Renewals Console can have an immediate impact on the bottom line, automating renewals management and incorporating subscription customers into ongoing marketing efforts,” said Craig Charlton, CEO of SugarCRM. “This is perfectly aligned with our no-touch information philosophy and Sugar’s commitment not only to understanding but also to where the CX industry is heading, but anticipating the needs of our customers as a result.”
Other highlights of the Winter ‘20 release include:
Sugar Market improves email bot click detection, allowing marketers to better understand prospect interactions by differentiating between bot and human traffic. Marketers get a more accurate picture of email campaign response rates, ensuring reliable marketing spend on activities that drive real engagement.
Sugar Serve provides valuable time-aware case tracking allowing customer service leaders to optimize team productivity by uncovering which types of cases require the most attention. Customer Service organizations can set up simple to complex business rules to measure and monitor first response SLAs and ensure customers’ SLA requirements are met.
Rounding out the release is the rollout of Sugar tagging on Sugar Mobile. Users can now create new tags, remove existing ones, and search by tag from their mobile device.
“We’re excited about this release for many reasons,” said Rich Green, Sugar Chief Product Officer and CTO. “Subscription models are becoming increasingly common in businesses worldwide, making native support for recurring revenue management critical. And underlying this and other new features are our time-aware CX technologies. We continue to make a differentiated impact on the CX landscape with our solutions, all with the goal of helping our customers create customers for life.”
About SugarCRM
SugarCRM is a customer experience solutions leader enabling businesses to deliver highly relevant, personalized attention throughout the lifetime of a relationship. Our innovative time-aware CX platform provides historical insight into customers, enabling companies to understand, strengthen and communicate more effectively. The result? Accelerated demand generation, increased revenue, superior customer care and elevated loyalty.
The Sugar Cloud portfolio aligns sales, marketing and customer service professionals to make business more predictable, supercharging growth. Sugar fuels midmarket and enterprise business by enabling high-impact, value-added activities that create customers for life.
Based in Silicon Valley, SugarCRM is backed by Accel-KKR. Nearly 4500 businesses in over 120 countries rely on SugarCRM.
To learn more visit https://www.sugarcrm.com or follow @SugarCRM.
NOTE: SugarCRM and the SugarCRM logo are registered trademarks of SugarCRM Inc. Third-party trademarks mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005068/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
